News

The approval is based on the data from an open label, multi-center Phase IV trial designed to evaluate the safety and immunogenicity of a single dose of Adacel

The acquisition elevates Actavis into a top-five position in the Thai generic pharmaceutical market, with leading positions in the ophthalmic and respiratory therapeutic categories and a strong cardiovascular

The research collaboration will be jointly funded by EMD Serono and Pfizer. SLE is a systemic autoimmune disease that can lead to LN, a kidney disorder that is

NESP, a long-acting erythropoiesis stimulating agent, was initially approved in July 2007. NESP is highly recognized for its safety and efficacy for treating anemia of chronic kidney disease

The acquisition positions Charles River as a full service, early-stage contract research organization (CRO), with integrated in vitro and in vivo capabilities from target discovery through preclinical development.

NCCN ORP vice president Diane Paul said this grant from Astellas and Medivation gives investigators at NCCN Member Institutions a remarkable opportunity to study the effectiveness of enzalutamide

Additionally, Eisai has assigned the patent right for its metabolic enzyme inhibitor E7727 to Otsuka. As part of the deal, Eisai will transfer to Otsuka its rights to

The announcement means a streamlining of the complex process of clinical research studies, making the setting up of such studies faster and easier by reducing bureaucracy and duplication.

Under the option agreement, the company has received a $1m, non-refundable option fee. If not exercised, the option that is subject to certain contingencies will expire on 30